22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › Arcus Biosciences, Inc. › 2024-2025

Arcus Biosciences, Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 211Asset managers, any item
  • 1,629Fund votes
  • June 10, 2025Meeting date

Results at a glance

Meeting of June 10, 2025: 6 items on Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2025: 6 passed (calculated).

Dissent

Notable dissent: 2 directors (19.9%, 17.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arcus Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Arcus Biosciences, Inc.

These tallies are Arcus Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arcus Biosciences, Inc. — official shareholder meeting results, meeting held June 10, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Yasunori Kaneko, M.D. 86,171,508---- 4,142,1918,580,999 95%Passed (calculated)—
Elect Director: Patrick Machado, J.D. 72,358,392---- 17,955,3078,580,999 80%Passed (calculated)—
Elect Director: Andrew Perlman, M.D., Ph.D 84,672,810---- 5,640,8898,580,999 94%Passed (calculated)—
Elect Director: Antoni Ribas, M.D., Ph.D. 74,827,393---- 15,486,3068,580,999 83%Passed (calculated)—
2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025 96,750,3271,952,359192,012 ---- 98%Passed (calculated)—
3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement 84,812,8095,446,38354,507 --8,580,999 94%Passed (calculated)—

Source: Arcus Biosciences, Inc., Form 8-K, filed with the SEC on June 12, 2025 — read the filing on EDGAR.

How asset managers voted at the Arcus Biosciences, Inc. 2024-2025 meeting

211 asset managers disclosed a vote on at least one Arcus Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Andrew Perlman, M.D., Ph.D

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 84,672,810WITHHELD: 5,640,889
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Election of Directors: Andrew Perlman, M.D., Ph.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Andrew Perlman, M.D., Ph.D”): 84,672,810 for, 5,640,889 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 23,481,581 for, 1,163,656 withheld, 11 abstained.

FOR
FOR: 23,481,581ABSTAIN: 11WITHHOLD: 1,163,656
Largest asset managers voting on “Election of Directors: Andrew Perlman, M.D., Ph.D.” at Arcus Biosciences, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock6,842,8590 00For
Vanguard6,561,9710 110For
Fidelity5,682,6560 00For
State Street1,275,3710 0527For
Dimensional00 0993,030Withhold
Charles Schwab651,4850 00For
Delaware/Macquarie379,1000 00For
Victory Capital169,1070 00For
Equitable88,1600 058,500Mixed
Columbia Threadneedle142,9610 00For
Jackson National115,0430 020,859Mixed
TIAA129,9300 00For
American Century105,3810 00For
QUANTITATIVE MASTER SERIES LLC95,5120 00For
MFS78,9520 00For
ALPS ETF Trust77,0400 00For
Prudential/PGIM60,6730 014,180Mixed
BNY Mellon71,1610 00For
Principal65,3610 00For
Direxion Shares ETF Trust59,3170 00For
Empower53,7070 00For
Exchange Place Advisors Trust49,9770 00For
Thrivent49,4290 00For
Lincoln Financial40,3000 07,101Mixed
Goldman Sachs46,6860 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Elect Director: Antoni Ribas, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD
FOR: 74,827,393WITHHELD: 15,486,306
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Election of Directors: Antoni Ribas, M.D., Ph.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Antoni Ribas, M.D., Ph.D.”): 74,827,393 for, 15,486,306 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 20,707,914 for, 3,937,313 withheld, 21 abstained.

FORWITHHOLD
FOR: 20,707,914ABSTAIN: 21WITHHOLD: 3,937,313
Largest asset managers voting on “Election of Directors: Antoni Ribas, M.D., Ph.D.” at Arcus Biosciences, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock6,842,8590 00For
Vanguard6,561,9610 210For
Fidelity5,677,4250 05,231For
State Street3,3090 01,272,589Withhold
Dimensional00 0993,030Withhold
Charles Schwab651,4850 00For
Delaware/Macquarie00 0379,100Withhold
Victory Capital00 0169,107Withhold
Equitable88,1600 058,500Mixed
Columbia Threadneedle00 0142,961Withhold
Jackson National115,0430 020,859Mixed
TIAA129,9300 00For
American Century00 0105,381Withhold
QUANTITATIVE MASTER SERIES LLC95,5120 00For
MFS00 078,952Withhold
ALPS ETF Trust00 077,040Withhold
Prudential/PGIM60,6730 014,180Mixed
BNY Mellon71,1610 00For
Principal00 065,361Withhold
Direxion Shares ETF Trust00 059,317Withhold
Empower00 053,707Withhold
Exchange Place Advisors Trust49,9770 00For
Thrivent00 049,429Withhold
Lincoln Financial00 047,401Withhold
Goldman Sachs46,6860 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Elect Director: Patrick Machado, J.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD
FOR: 72,358,392WITHHELD: 17,955,307
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Election of Directors: Patrick Machado, J.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Patrick Machado, J.D.”): 72,358,392 for, 17,955,307 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 80% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 20,023,416 for, 4,621,809 withheld, 23 abstained.

FORWITHHOLD
FOR: 20,023,416ABSTAIN: 23WITHHOLD: 4,621,809
Largest asset managers voting on “Election of Directors: Patrick Machado, J.D.” at Arcus Biosciences, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock6,436,8920 0405,967Mixed
Vanguard6,558,1200 233,838For
Fidelity5,667,6750 014,981For
State Street3,3090 01,272,589Withhold
Dimensional00 0993,030Withhold
Charles Schwab651,4850 00For
Delaware/Macquarie00 0379,100Withhold
Victory Capital00 0169,107Withhold
Equitable88,1600 058,500Mixed
Columbia Threadneedle142,9610 00For
Jackson National00 0135,902Withhold
TIAA129,9300 00For
American Century00 0105,381Withhold
QUANTITATIVE MASTER SERIES LLC95,5120 00For
MFS00 078,952Withhold
ALPS ETF Trust00 077,040Withhold
Prudential/PGIM60,6730 014,180Mixed
BNY Mellon00 071,161Withhold
Principal00 065,361Withhold
Direxion Shares ETF Trust00 059,317Withhold
Empower00 053,707Withhold
Exchange Place Advisors Trust49,9770 00For
Thrivent00 049,429Withhold
Lincoln Financial00 047,401Withhold
Goldman Sachs00 046,686Withhold

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Elect Director: Yasunori Kaneko, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 86,171,508WITHHELD: 4,142,191
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Election of Directors: Yasunori Kaneko, M.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Yasunori Kaneko, M.D.”): 86,171,508 for, 4,142,191 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 23,481,221 for, 1,164,020 withheld, 7 abstained.

FOR
FOR: 23,481,221ABSTAIN: 7WITHHOLD: 1,164,020
Largest asset managers voting on “Election of Directors: Yasunori Kaneko, M.D.” at Arcus Biosciences, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock6,842,8590 00For
Vanguard6,561,9750 70For
Fidelity5,682,6560 00For
State Street1,275,3710 0527For
Dimensional00 0993,030Withhold
Charles Schwab651,4850 00For
Delaware/Macquarie379,1000 00For
Victory Capital169,1070 00For
Equitable88,1600 058,500Mixed
Columbia Threadneedle142,9610 00For
Jackson National115,0430 020,859Mixed
TIAA129,9300 00For
American Century105,3810 00For
QUANTITATIVE MASTER SERIES LLC95,5120 00For
MFS78,9520 00For
ALPS ETF Trust77,0400 00For
Prudential/PGIM60,6730 014,180Mixed
BNY Mellon71,1610 00For
Principal65,3610 00For
Direxion Shares ETF Trust59,3170 00For
Empower53,7070 00For
Exchange Place Advisors Trust49,9770 00For
Thrivent49,4290 00For
Lincoln Financial40,3000 07,101Mixed
Goldman Sachs46,6860 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 84,812,809AGAINST: 5,446,383

Prior year: 96.3% for (June 6, 2024 meeting) ▼ 2.3 pts

Details: description as filed, official tally, votes by 211 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

Arcus Biosciences, Inc.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 84,812,809 for, 5,446,383 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 72 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSE” at Arcus Biosciences, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock6,842,8590 00For
Vanguard6,558,1333,849 00For
Fidelity5,682,6560 00For
State Street1,275,286612 00For
Dimensional993,0300 00For
Charles Schwab651,4850 00For
Delaware/Macquarie379,1000 00For
Victory Capital169,1070 00For
Equitable146,6600 00For
Columbia Threadneedle142,9610 00For
Jackson National135,9020 00For
TIAA0129,930 00Against
American Century105,3810 00For
QUANTITATIVE MASTER SERIES LLC95,5120 00For
MFS78,9520 00For
ALPS ETF Trust77,0400 00For
Prudential/PGIM14,18060,673 00Mixed
BNY Mellon71,1610 00For
Principal65,3610 00For
Direxion Shares ETF Trust59,3170 00For
Empower53,7070 00For
Exchange Place Advisors Trust49,9770 00For
Thrivent49,4290 00For
Lincoln Financial47,4010 00For
Goldman Sachs46,6860 00For

Fund voting reports, all 72 managers: 24,388,198 for, 245,795 against, 11,254 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 165 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSE” at Arcus Biosciences, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
GILEAD SCIENCES, INC.31,424,7600 00For
Woodline Partners LP6,292,6180 00For
Fidelity4,421,4820 00For
SUVRETTA CAPITAL MANAGEMENT, LLC3,398,5030 00For
State Street2,443,13422,859 00For
Point722,081,0160 00For
BlackRock1,952,83614,443 00For
Siren, L.L.C.00 00Not Voted
GEODE CAPITAL MANAGEMENT, LLC1,409,6680 00For
BNP Paribas Asset Management Holding S.A.01,396,275 00Against
RA CAPITAL MANAGEMENT, L.P.1,029,4000 00For
JACOBS LEVY EQUITY MANAGEMENT, INC744,3010 00For
Charles Schwab741,2310 00For
DAFNA Capital Management LLC627,6260 00For
Sofinnova Investments, Inc.503,1010 00For
Wellington472,5440 00For
MELLON INVESTMENTS Corp384,9240 00For
Northern Trust382,230459 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST379,1000 00For
PRINCIPAL GLOBAL INVESTORS336,0850 00For
Granahan Investment Management, LLC308,3200 00For
NORDEA INVESTMENT MANAGEMENT AB0281,869 00Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC0255,064 00Against
AXA INVESTMENT MANAGERS UK Ltd0231,608 00Against
PUBLIC SECTOR PENSION INVESTMENT BOARD229,1240 00For

Institutional-manager reports, all 165 managers: 62,603,305 for, 3,032,532 against, 575 abstained, 1,612,077 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 96,750,327AGAINST: 1,952,359

Prior year: 98.5% for (June 6, 2024 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.

Arcus Biosciences, Inc.’s own tally for this item (“2. The ratification of the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December”): 96,750,327 for, 1,952,359 against, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 23,821,968 for, 812,026 against, 11,254 abstained.

FOR
FOR: 23,821,968AGAINST: 812,026ABSTAIN: 11,254
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDE” at Arcus Biosciences, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock6,842,8590 00For
Vanguard6,558,1403,842 00For
Fidelity5,682,6560 00For
State Street1,275,81385 00For
Dimensional993,0300 00For
Charles Schwab0651,485 00Against
Delaware/Macquarie379,1000 00For
Victory Capital169,1070 00For
Equitable146,6600 00For
Columbia Threadneedle142,9610 00For
Jackson National135,9020 00For
TIAA129,9300 00For
American Century105,3810 00For
QUANTITATIVE MASTER SERIES LLC95,5120 00For
MFS78,9520 00For
ALPS ETF Trust77,0400 00For
Prudential/PGIM74,8530 00For
BNY Mellon71,1610 00For
Principal65,3610 00For
Direxion Shares ETF Trust59,3170 00For
Empower53,7070 00For
Exchange Place Advisors Trust049,977 00Against
Thrivent49,4290 00For
Lincoln Financial47,4010 00For
Goldman Sachs46,6860 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Largest Arcus Biosciences, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 105,900,000 shares outstanding at the time of that meeting.

Fund voting reports: top Arcus Biosciences, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1BlackRock 6.46%
2Vanguard 6.20%
3Fidelity 5.37%
4State Street 1.20%
5Dimensional 0.94%
6Charles Schwab 0.62%
7Delaware/Macquarie 0.36%
8Victory Capital 0.16%
9Equitable 0.14%
10Columbia Threadneedle 0.13%
Institutional-manager reports: top Arcus Biosciences, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE…”, 2024-2025
#Asset manager % of shares outstanding
1GILEAD SCIENCES, INC. 29.67%
2Woodline Partners LP 5.94%
3Fidelity 4.18%
4SUVRETTA CAPITAL MANAGEMENT, LLC 3.21%
5State Street 2.33%
6Point72 1.97%
7BlackRock 1.86%
8Siren, L.L.C. 1.52%
9GEODE CAPITAL MANAGEMENT, LLC 1.33%
10BNP Paribas Asset Management Holding S.A. 1.32%

Reported Arcus Biosciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Arcus Biosciences, Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
GILEAD SCIENCES, INC.31,424,760 29.67%Schedule 13D, filed November 5, 2025
BlackRock, Inc.12,736,927 12.03%Schedule 13G, filed January 8, 2026
The Vanguard Group, Inc.6,161,943 5.82%Proxy statement (DEF 14A), table as of March 1, 2025
FMR (Fidelity)4,456,846 4.21%Form 13F, quarter ended March 31, 2025
State Street3,696,479 3.49%Form 13F, quarter ended March 31, 2025
Terry Rosen, Ph.D.2,571,357 2.43%Proxy statement (DEF 14A), table as of March 1, 2025
Dimensional Fund Advisors1,722,083 1.63%Form 13F, quarter ended March 31, 2025
Juan Carlos Jaen, Ph.D.1,444,741 1.36%Proxy statement (DEF 14A), table as of March 1, 2025
Geode Capital1,389,232 1.31%Form 13F, quarter ended March 31, 2025
Wellington Management1,082,808 1.02%Form 13F, quarter ended March 31, 2025

Percentages above are of 105,900,000 shares outstanding, as reported by Arcus Biosciences, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Arcus Biosciences, Inc.'s shareholder meeting held June 10, 2025, in the 2024-2025 proxy season, 211 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,629 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcus Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcus Biosciences, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Arcus Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “Arcus Biosciences (RCUS) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arcus-biosciences-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.